Chemomab Therapeutics (CMMB) Research & Development (2017 - 2026)

Chemomab Therapeutics (CMMB) has reported Research & Development for 10 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 11.27% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $4.1 million (down 54.36% YoY), and the FY2025 full-year result was $5.8 million, down 48.5% from the prior year.
• Research & Development climbed to $1.1 million in Q2 2026 per CMMB's latest filing, from $925000.0 in the prior quarter.
• Across five years, Research & Development topped out at $6.9 million in Q1 2023 and bottomed at $925000.0 in Q1 2026.
• Historically, Research & Development has averaged $3.0 million across 5 years, with a median of $2.9 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 264.69% in 2022, then plunged 66.15% in 2025.
• Over 5 years, Research & Development stood at $5.9 million in 2022, then sank by 47.46% to $3.1 million in 2023, then decreased by 22.15% to $2.4 million in 2024, then tumbled by 54.67% to $1.1 million in 2025, then grew by 4.48% to $1.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $1.1 million, $925000.0, and $1.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.